TLR3 and influenza: In experimental animals, the administration of TLR3 agonists is effective in reducing the damage caused by influenza[23,24] because they inhibit the replication of mouse-adapted laboratory influenza A viruses and clinical isolates from humans (including considerably virulent strains with pandemic potential).